V3V.DE
VITA 34 AG [V3V.DE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
V3V.DE Stock Summary
Top 10 Correlated Stocks
V3V.DE
In the News
V3V.DE Financial details
Company Rating
-
Market Cap
83.32M
Income
-25.18M
Revenue
74.86M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
815
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-3.35
Forward P/E
-
PEG
4.01
P/S
1.25
P/B
6.92
P/C
-
P/FCF
-66.05
Quick Ratio
0.05
Current Ratio
0.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.59
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
30.56%
Revenue Q/Q
11.15%
EPS Q/Q
32.8%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-17%
ROE
-181%
ROC
-0.22%
Gross Margin
14%
Oper. Margin
-29%
Profit Margin
-34%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.69-7.32
52W High
-43.71%
52W Low
+31.33%
RSI
46
Rel Volume
0.01
Avg Volume
1.87K
Volume
10
Perf Week
-1.01%
Perf Month
1.03%
Perf Quarter
-4.83%
Perf Half Y
-7.94%
-
-
-
-
Beta
0.602
-
-
Volatility
0.02%, 0.12%
Prev Close
0%
Price
3.94
Change
0%
Company Profile
- Volume Average 1.87K
- Market Capitalization 83.32M
- Employee 815
- CEO Mr. Jakub Julian Baran
- Headquarters Leipzig,DE
- IPO Date 2007-03-27
-
Website
https://www.vita34.de 
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
